CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 Study Offers Insights on Health Problems among AYA Cancer Survivors August 7, 2020 Thinking outside the chromosome – how ecDNA is challenging conventional thinking November 11, 2022 How We’re Working to Help People With Cancer Across the World April 7, 2021 Load more HOT NEWS Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information
